tirzepatide and psoriasis skyrizi We see this anecdotally but nice to see trial data coming out. My The Psoriasis Pipeline Heats Up:

The accumulation of the results of these ongoing cardiovascular outcome trials should be able to answer questions about cardiovascular benefits of GLP-1 RAs that were strongly suggested by previous preclinical and clinical studies and their possibility to lower the excessive cardiovascular burden in patients with T2D

BMJ 315 (7109), 629634

The researchers used advanced statistical methods to balance out differences between groups such as age, sex, body weight and other health factors so they could more accurately compare outcomes

Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes

Not everyone needs to reach the maximum dose